0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Interim Analyses and Publication of Clinical Trials

Frederic M. Quitkin, MD; Michael R. Liebowitz, MD
Arch Gen Psychiatry. 1986;43(6):613-614. doi:10.1001/archpsyc.1986.01800060107014.
Text Size: A A A
Published online

ABSTRACT

In Reply.—  The issues raised by Dr Paykel are relevant and worthy of discussion. First he asks whether knowledge of the results may prejudice blindness and evaluation of remaining cases in the study. It is suggested this is a particular problem in our study since the two drugs have different side-effect profiles. It is true that the profile of side effects of these drugs are different enough so that a portion of the time the rater might guess which drug the patient is taking. However, it is unclear how knowledge of outcome enhances this potential source of bias. Keeping raters blind to outcome will not diminish the likelihood of their assuming that certain side-effect profiles are associated with treatment with phenelzine and others with imipramine.We have attempted to deal with this possible bias by extending the trial for responders. Patients who are considered to have benefited from the treatment, defined as

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();